Korean J Intern Med.
2019 Jul;34(4):885-893. 10.3904/kjim.2017.036.
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. bhumsuk@snu.ac.kr
- 2Department of Internal Medicine, Kyung Hee University Graduate School of Medicine, Seoul, Korea.
- 3Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- 5Department of Pathology, Seoul National University Hospital, Seoul, Korea.
- KMID: 2457319
- DOI: http://doi.org/10.3904/kjim.2017.036
Abstract
- BACKGROUND/AIMS
This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
METHODS
The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor's progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria.
RESULTS
IRR was not associated with overall survival (OS) or progression-free survival (PFS) of DLBCL patients as compared to those who did not have IRR (OS: median 78.0 months vs. 69.0 months, p = 0.700; PFS: median 65.4 months vs. 64.0 months, p = 0.901). IRR grade did not affect OS or PFS. B symptoms was independently associated with IRR (hazard ratio [HR], 1.850; 95% confidence interval [CI], 1.041 to 3.290; p = 0.036). Further, bone marrow involvement was independently associated with re-IRR (HR, 4.904; 95% CI, 0.767 to 3.118; p = 0.029).
CONCLUSIONS
Our study shows that IRR of rituximab is not associated with OS or PFS of DLBCL patients who received R-CHOP. Furthermore, our study suggests a need for more careful observation for IRR in patients with B symptoms or bone marrow involvement.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
- Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
- A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy
- A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
- Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
